| Autor: |
Berkane, Nadia, Carlier, Patrick, Verstraete, Lieve, Mathieu, Emmanuelle, Heim, Nazbanou, Uzan, Serge |
| Zdroj: |
Birth Defects Research Part A: Clinical and Molecular Teratology; August 2004, Vol. 70 Issue: 8 p547-549, 3p |
| Abstrakt: |
Published cases suggest that the use of angiotensin II receptor antagonists is fetotoxic during the third trimester, but not in early pregnancy. CASE: We report a case in which the adverse fetal effect of angiotensin II receptor antagonist treatment was reversed. A woman with chronic hypertension was treated with valsartan until gestation week (GW) 20, when a complete anhydramnios was observed. Six days after interruption of the treatment, amniotic fluid reappeared. It reached a normal level at GW 23.5. The plasmatic creatinine level and the renal ultrasound examination were within normal limits at the six‐month follow‐up.Whereas angiotensin‐II‐receptor antagonist generates a severe renal toxicity, this case suggests that, at least in the first half of pregnancy, these effects can be reversed. Birth Defects Research (Part A) 67:, 2004. © 2004 Wiley‐Liss, Inc. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text